Clinical trials: Renal Tumors
Kidney Cancer
Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have progressive…
- Trial name
- NCT00005056
- Testing
- bryostatin 1
- Where
- 2 sites in United Kingdom
- Sponsor
- Cancer Research UK
Renal Cell Carcinoma
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint…
- Trial name
- NCT04987203
- Testing
- Tivozanib, Nivolumab
- Where
- 139 sites in United States, Argentina and 14 more
- Volunteers
- 343 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Renal Cell Carcinoma (RCC)
Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline After Partial Nephrectomy in Renal Cell Carcinoma: A Multicenter Development/Validation Study
The goal of this observational study is to explore the relationship between CT-based radiomics and postoperative renal function changes in patients with localized renal cell carcinoma (RCC) undergoing partial nephrectomy (PN).
- Trial name
- NCT07117786
- Testing
- CT Contrast, Computed Tomography
- Volunteers
- 1,437 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Kidney Cancer, Post-surgical Pain
ESP Block for Laparoscopic Nephrectomy Surgeries
Nephrectomy (kidney removal) is one of the most common surgical procedures in urologic practice. Recent advances in laparoscopic (keyhole) procedures have resulted in a significant decrease in open nephrectomies.
- Trial name
- ESPB (NCT04085237)
- Testing
- Ropivacaine injection
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Carcinoma, Renal Cell
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC
- Trial name
- NCT00591188
- Testing
- capecitabine, interferon-alpha
- Where
- Russia
- Volunteers
- 49 people
- Sponsor
- Kidney Cancer Research Bureau
Metastatic Renal Cell Carcinoma
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
This study aims to report the effects of immediate or delayed exercise training on patients with advanced or metastatic renal cell carcinoma who are receiving nivolumab and ipilimumab.
- Trial name
- INTERVAL (NCT03692338)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Renal Neoplasms, Localized Kidney Tumors
Effect of Non-Clamping and Sutureless Technique on Postoperative Renal Function in Robot-Assisted Partial Nephrectomy
Partial nephrectomy is an operation that removes a kidney tumor while leaving the rest of the kidney in place. It is used to treat selected patients with small tumors confined to the kidney.
- Trial name
- NCT07888608
- Testing
- Off-Clamp, Sutureless Robot-Assisted Partial Nephrectomy, Conventional Robot-Assisted Partial Nephrectomy With Artery Clamping and Sutured Reconstruction
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Shao Pengfei
Renal Cell Carcinoma, Adrenal Tumor
Research on the Effectiveness and Safety of Remote Control of Domestic Surgical Robot System for Urinary Surgery
One-arm clinical trial was adopted in this study. The surgeon performed remote urological surgery for patients through domestically produced "MicroHand" surgical robot system (Shandong Weigao Co., Ltd).
- Conditions
- Renal Cell Carcinoma, Adrenal Tumor, Nonfunctioning Kidney
- Trial name
- NCT04804163
- Testing
- telesurgery by domestic robot
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Metastatic Renal Cell Carcinoma
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
The primary objective of this study is to evaluate the incidence of high-grade (i.e. Grade 3-4 and Grade 5 of CTCAE v4.0) adverse reactions of interest in patients with metastatic RCC who have progressed during or after receiving…
- Trial name
- NIVOREN (NCT03013335)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 730 people
- Sponsor
- UNICANCER
Renal Cell Carcinoma
Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study. is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC…
- Trial name
- RUBIKID (NCT07346404)
- Testing
- 82-Rb injection
- Where
- 2 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carcinoid, Neuroendocrine
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.
- Trial name
- NCT00314925
- Testing
- Seneca Valley Virus (biological agent)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Neotropix
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Renal Cell Carcinoma
Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in England
The present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (aRCC) patients treated with cabozantinib or axitinib…
- Trial name
- NCT04637204
- Testing
- Cabozantinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 1,540 people
- Sponsor
- Ipsen
Renal Cell Carcinoma
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
This is an open-label, non-controlled, non-randomized, phase I dose-finding, of Cabometyx + Avelumab, to establish safety, feasibility, and the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of Cabometyx in…
- Trial name
- NCT03200587
- Testing
- Avelumab, Cabozantinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Metastatic Renal Cancer
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Summary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs.
- Trial name
- NCT06959433
- Testing
- Lu-177 PSMA-617
- Volunteers
- 20 people
- Sponsor
- Ankara University
Metastatic Clear Cell Renal Carcinoma
A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This is very difficult to treat and almost all patients will die of their disease within 2 years of the diagnosis.
- Trial name
- ZEBRA (NCT01793636)
- Testing
- AZD2014, Everolimus
- Where
- 9 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Queen Mary University of London
Kidney Cancer
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2).
- Trial name
- RESTRICT (NCT04922307)
- Testing
- Blood Sparing Protocol, Standard Blood Replacement
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanderbilt University Medical Center
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
This is an open label single arm, multicenter, phase II study designet To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
- Trial name
- BREAKPOINT (NCT03463681)
- Testing
- Cabometyx
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.